AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings in the application:

1.-13. Canceled.

14. (Currently Amended) A method of treating a patient with a solid tumor cancer selected from the group consisting of malignant melanoma, stomach cancer, breast cancer, ovarian cancer, lung cancer, and colorectal cancer or leukemia, comprising the step of administering a pharmaceutically effective amount of a compound of 7-trimethylsilyl-10-hydroxy camptothecin or 7-tert-butyldimethylsilyl-10-hydroxy camptothecin.

15.-39. (Canceled)

- 40. (Currently Amended) The method of Claim 14, wherein the compound is 7-tert-butyldimethylsilyl-10-hydroxy camptothecin.
- 41. (New) The method of claim 14 wherein the patient has a solid tumor cancer selected from the group consisting of malignant melanoma, stomach cancer, breast cancer, ovarian cancer, lung cancer, and colorectal cancer.
- 42. (New) The method of claim 41 wherein the solid tumor cancer is malignant melanoma.
- 43. (New) The method of claim 41 wherein the solid tumor cancer is stomach cancer.
- 44. (New) The method of claim 41 wherein the solid tumor cancer is breast cancer.
- 45. (New) The method of claim 41 wherein the solid tumor cancer is ovarian cancer.

- 46. (New) The method of claim 41 wherein the solid tumor cancer is lung cancer.
- 47. (New) The method of claim 41 wherein the solid tumor cancer is colorectal cancer.
- 48. (New) The method of Claim 41, wherein the compound is 7-tert-butyldimethylsilyl-10-hydroxy camptothecin.
- 49. (New) A method of treating a patient with a solid tumor cancer, comprising the step of administering a pharmaceutically effective amount of a compound of 7-trimethylsilyl-10-hydroxy camptothecin or 7-tert-butyldimethylsilyl-10-hydroxy camptothecin.
- 50. (New) The method of Claim 49, wherein the compound is 7-tert-butyldimethylsilyl-10-hydroxy camptothecin.
- 51. (New) A method of administering a topoisomerase I inhibiting agent to a mammal comprising the step of administering a pharmaceutically effective amount of a compound of 7-trimethylsilyl-10-hydroxy camptothecin or 7-tert-butyldimethylsilyl-10-hydroxy camptothecin.
- 52. (New) The method of Claim 51, wherein the compound is 7-tert-butyldimethylsilyl-10-hydroxy camptothecin.